Intravitreal Bevacizumab for Traumatic Choroidal Rupture

Area of Science:

• Ophthalmology
• Retinal Diseases
• Trauma Care

Background:

• Blunt ocular trauma can cause traumatic choroidal rupture, leading to vision loss.
• Subretinal fluid accumulation and hemorrhage are common complications impacting visual acuity.
• Choroidal neovascularization (CNV) is a potential long-term sequela, though not always present initially.

Observation:

• A 14-year-old male presented with decreased vision after blunt ocular trauma.
• Funduscopic examination and OCT revealed macular choroidal rupture with subretinal fluid and hemorrhage.
• Despite no evidence of active CNV, persistent serous retinal detachment caused visual impairment.

Findings:

• Intravitreal bevacizumab (1.25 mg) injection was administered for persistent subretinal fluid.
• Significant reduction in subretinal fluid and visual acuity improvement to 20/30 occurred within one week.
• Complete resolution of subretinal fluid and visual recovery to 20/20 were achieved by 6 weeks, with sustained results at 1 year.

Implications:

• Early intravitreal bevacizumab may be an effective treatment for vision loss due to traumatic choroidal rupture with subretinal fluid.
• This approach can be beneficial even in the absence of confirmed choroidal neovascularization.
• The treatment demonstrated a favorable safety profile without ocular or systemic complications.